Bepirovirsen (Hibsago) Prescribing Information: Indications, Boxed Warnings, Dose Adjustment and Monitoring
Bepirovirsen(Hibsago)is a subcutaneous injectable antisense oligonucleotide(150mg/mL)that degrades HBV mRNA to suppress viral replication.It must be combined with nucleos(t)ide reverse transcriptase inhibitors(NrtI)and cannot be used as monotherapy.
Boxed Warnings
On-treatment hepatic flares:Marked ALT elevations mostly occur within the first 12 weeks,often accompanied by HBsAg decline.Contraindicated in acute liver injury or cirrhosis.Monitor liver function closely;interrupt,reduce or permanently discontinue as needed.
Thrombocytopenia:Sudden,life-threatening platelet decline may occur.Baseline platelets must be≥100×10⁹/L.Monitor regularly during treatment;permanently discontinue if platelets<50×10⁹/L.
Indications
For non-cirrhoticadults with chronic HBV infection who have received NrtI for≥6 months,suppressed HBV DNA,and HBsAg≤3000IU/mL.
Limitations:Not recommended for patients<18 years,HBV/HDV co-infection;safety not established in HBV/HCV co-infection;contraindicated in cirrhosis and decompensated liver disease;monotherapy prohibited.
Baseline Screening and Monitoring
Baseline tests:HBsAg quantification,HBV DNA,ALT,AST,bilirubin,platelet count,uACR,eGFR;confirm absence of cirrhosis.
During treatment:ALT/bilirubin weekly until week 12,then every 2 weeks until week 24;platelets weekly until week 24;eGFR every 2 weeks until week 24;assess proteinuria periodically.
Post-treatment:Recheck abnormal parameters at weeks 4,12 and 24 after discontinuation.
Dosage and Administration
Subcutaneous injection.Allow to warm to room temperature≥30 minutes before use;inspect for clarity;rotate injection sites(abdomen,thigh).
Weeks 1–2:300mg(two 150mg injections),twice weekly,3–4 days apart.
Weeks 3–24:300mg(two 150mg injections),once weekly.
Continue NrtI throughout.If HBsAg≥1IU/mL at week 12,consider early discontinuation.Stop bepirovirsen after 24 weeks and continue NrtI for at least 24 weeks.If a dose is missed,administer as soon as possible;skip if<3 days to next dose.
Dose Modification
Hepatic abnormalities:Based on ALT magnitude and bilirubin levels—continue,hold,resume at reduced dose,or permanently discontinue.
Thrombocytopenia:Hold if 75–<100×10⁹/L and resume at full dose after recovery;permanently discontinue if<50×10⁹/L;test platelets immediately if bleeding signs appear.
Renal decline:Hold if eGFR decreases≥30%from baseline(confirmed twice);resume after recovery.
Adverse Reactions
Common(≥10%):Injection site reactions,pyrexia,fatigue,headache.
Laboratory abnormalities:ALT elevation,platelet decline,neutrophil reduction,eGFR decrease.
Immune-related risks:Flu-like symptoms,vasculitis,immune thrombocytopenia,autoimmune hemolytic anemia.
Precautions
Suspected vasculitis requires permanent discontinuation.
Improper injection may cause omental infarction;rotate sites strictly every week.
HBV exacerbation may occur after stopping NrtI;monitor closely for 1 year post-NrtI cessation.
Do not stop NrtI in HBV/HIV co-infection without HIV specialist advice;avoid in HDV co-infection.
Do not combine with peginterferon alfa-2a;monitor for bleeding with anticoagulants/antiplatelets and for renal worsening with nephrotoxic drugs.
Special Populations
Pregnancy/lactation:Limited data;weigh risks and benefits.Elderly patients show slightly lower efficacy;safety profile similar to younger adults.
Hepatic impairment:Contraindicated in cirrhosis and Child-Pugh A/B/C;exposure reduced in moderate impairment.
Renal impairment:Insufficient data in moderate/severe impairment;drug may worsen renal function;avoid in severe renal disease.
Pediatrics:Safety not established in patients<18 years.
Drug Interactions
Not metabolized by CYP450,not a transporter substrate;no significant PK interaction with NrtI.Avoid peginterferon alfa-2a.Enhanced monitoring required with anticoagulants,antiplatelets and nephrotoxic agents.
Storage
Before dispensing:refrigerate at 2–8°C,protected from light;do not freeze or shake.After dispensing:store at≤30°C,protected from light.Administer within 6 hours of removal;discard if expired.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)